Skip to main content
Article
High flow nasal oxygen therapy utilization: 7-year experience at a community teaching hospital
All Scholarly Works
  • Mihaela Stefan, MD, Baystate Health
  • Bogdan Tiru, MD, Baystate Health
  • Jennifer Friderici, Baystate Health
  • Peter Lindenauer, Baystate Health
  • Jay Steingrub, MD, Baystate Health
Document Type
Article, Peer-reviewed
Publication Date
4-1-2018
Abstract

OBJECTIVE:

To examine the use of high flow nasal cannula oxygen therapy (HFNC) between 2008 and 2014 in patients 18 years or older at a community teaching hospital. METHODS:

Yearly utilization rates of HFNC, noninvasive ventilation (NIV) and invasive mechanical ventilation (IMV) were calculated among admissions with a set of cardiopulmonary diagnoses (heart failure, COPD, asthma or pneumonia). RESULTS:

Among the 41,711 admissions with at least one of the above cardiopulmonary condition, HFNC was utilized in 1,128 or 27.0/1000; NIV was used in an average of 169/1000 and IMV in 231/1000. HFNC was accompanied by IMV or NIV 71.3% of the time. From 2008 to 2014 HFNC utilization increased an average of 17.5% annually; NIV increased by 10.2% annually while IMV's utilization increased by 1.6% annually. The highest rate of change in HFNC use was among admissions with pneumonia and those with COPD. CONCLUSION:

HFNC utilization increased steadily over a 7-year period at our hospital. Frequently, HFNC therapy was used in combination with other ventilatory modes to support patients' respiration. Similar with other technologies in healthcare, the uptake of HFNC has preceded the evidence from robust clinical trials.

PMID
29431543
Citation Information
Stefan MS, Eckert P, Tiru B, Friderici J, Lindenauer PK, Steingrub JS. High flow nasal oxygen therapy utilization: 7-year experience at a community teaching hospital. Hosp Pract (1995). 2018 Apr;46(2):73-76.